Trials / Completed
CompletedNCT01847807
The Organ Protection of Astragalus in Subjects With Metabolic Syndrome
The Cardiac and Kidney Protection of Astragalus in Subjects With Metabolic Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- LanZhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | low dose Astragalus | |
| DRUG | high dose astagalus |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2015-06-01
- First posted
- 2013-05-07
- Last updated
- 2015-10-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01847807. Inclusion in this directory is not an endorsement.